Log in to search using one of your social media accounts:

 

Could a blood test in middle age predict dementia risk?
Conclusion Inflammation in the body is a response to injury or disease. But if the body is constantly in an inflammatory state, it can harm blood vessels and lead to heart disease. This study suggests high levels of inflammation over the long term might also damage the brain. That's not surprising – what's good for the heart is usually good for the brain, and we already know exercising, avoiding high blood pressure and eating healthily may help protect the brain. Studies like this will help researchers work out more precisely what's happening in the brain when people experience memory loss or dementia. But this study...
Source: NHS News Feed - November 2, 2017 Category: Consumer Health News Tags: Lifestyle/exercise Source Type: news

Celebrating 10 years of success for Infusion
As the business took off, more space was needed, and the company moved in 2009 to “real” office space just up the road in Haddam, CT, across the street from the Connecticut River, eventually employing a staff of 10 that year. A year later, in 2010, Infusion had doubled in size and became part of the UDG/Ashfield family. Infusion continued to grow at a steady pace into new therapeutic areas with more clients and employees, and in October 2016, Infusion left its country setting and moved into larger corporate offices in downtown Middletown, CT. Our staff now comprises 45 people and includes account executives, me...
Source: Ashfield Healthcare News - July 11, 2017 Category: Pharmaceuticals Authors: Sarah Edwards Tags: Ashfield Source Type: news

Vonvendi (von Willebrand factor (Recombinant) for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 19, 2017 Category: Drugs & Pharmacology Source Type: news

Belgium ’s Ablynx submits marketing authorisation application for caplacizumab approval
Belgium-based Ablynx has submitted a marketing authorisation application (MAA) to the European Medicines Agency (EMA) for approval of caplacizumab anti-von Willebrand factor (vWF) Nanobody to treat acquired thrombotic thrombocytopenic purpura (aTTP). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 7, 2017 Category: Pharmaceuticals Source Type: news

Severe Hyponatremic Encephalopathy following Bowel Prep for Colonoscopy
CONCLUSION This case highlights the need for physicians to be aware of the potential electrolyte disturbances that can occur in susceptible individuals during bowel prep for a colonoscopy. Any patient presenting with acute altered mental status in this setting should receive prompt electrolyte measurements and treatment of hyponatremia with hypertonic saline to help minimize associated morbidity. REFERENCES Adrogue HJ, Madias NE. Hyponatremia. N Engl J Med. 2000;342 (21):1581-1589. Frizelle FA, Colls BM. Hyponatremia and seizures after bowel preparation: report of three cases. Dis Colon Rectum. 2005;48(2):393-396. doi:...
Source: EPMonthly.com - November 25, 2016 Category: Emergency Medicine Authors: Matt McGahen Tags: Uncategorized Source Type: news

Von Willebrand Disease: the Under-the-Radar Bleeding Disorder
Constant nosebleeds, persistent bruising and super-heavy periods are signs you shouldn ’t dismiss. (Source: U.S. News - Health)
Source: U.S. News - Health - October 7, 2016 Category: Consumer Health News Authors: Lisa Esposito Source Type: news

Vonvendi, the first and only recombinant treatment for adults affected by von Willebrand disease, launches in the USA
Shire plc (LSE: SHP, NASDAQ: SHPG), continuing on Baxalta's long-standing commitment to the bleeding disorder community, today announced the U.S. launch of VONVENDI [von Willebrand factor (Recombinant)], the only recombinant treatment for adults living with von Willebrand disease (VWD). (Source: World Pharma News)
Source: World Pharma News - August 9, 2016 Category: Pharmaceuticals Tags: Featured Shire Business and Industry Source Type: news

USMLE Step 2: This month ’s question to beat
Getting ready for the United States Medical Licensing Examination ® (USMLE®) Step 2 is no easy feat, but we’re sharing expert insights to help give you a leg up. Take a look at the exclusive scoop on this month’s most-missed USMLE Step 2 test prep question. Think you have what it takes to rise above your peers? Test your USMLE knowledge, and view an expert v ideo explanation of the answer from Kaplan Medical. Once you ’ve got this question under your belt, be sure to test your knowledge with  other posts in this series . Ready. Set. Go. This month ’s question that stumped most st...
Source: AMA Wire - July 25, 2016 Category: Journals (General) Authors: Troy Parks Source Type: news

Mechanism proposed for microvascular thrombosis in thrombotic thrombocytopenic purpura
In patients with acquired autoimmune thrombotic thrombocytopenic purpura, elevated plasma levels of human neutrophil proteins 1-3 inhibit proteolytic cleavage of von Willebrand factor by ADAMTS13, Vikram G. Pillai, PhD, of the University of Alabama at Birmingham, and colleagues reported. The... (Source: Skin and Allergy News)
Source: Skin and Allergy News - July 8, 2016 Category: Dermatology Source Type: news

Making Pharma Personal
Paul Perreault, CEO and Managing Director of biotherapies company CSL Behring, often receives messages from people celebrating the great landmarks in their lives. There is nothing so very extraordinary about that – except these are from patients whom he has helped during his time in the business. “I wasn’t always an executive, so I started in the business, and I know patients and their families personally, across the country,” he begins. “At different levels of jobs that I’ve had in the organization, I’ve interacted with patients on a very direct and one-on-one level. And I was aro...
Source: EyeForPharma - April 28, 2016 Category: Pharmaceuticals Authors: Adam Hill Source Type: news

Wilate (von Willebrand Factor/Coagulation Factor VIII Complex (Human)) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 7, 2016 Category: Drugs & Pharmacology Source Type: news

US approval for bleeding disorder drug
(Max Delbrück Center for Molecular Medicine in the Helmholtz Association) 'VONVENDI,' the new drug from Baxalta Incorporated, has just been approved by the United States Food and Drug Administration. It is the first, and so far the only, recombinant protein for the treatment of von Willebrand disease, and offers those affected a new therapeutic option for the first time in more than 10 years. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 21, 2015 Category: Global & Universal Source Type: news

Vonvendi (von Willebrand factor (Recombinant) for Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 16, 2015 Category: Drugs & Pharmacology Source Type: news

Why Is It Called Christmas Disease?
Discussion Too much or too little causes the important homeostatic balance of life to be upset. This is true of the interactions between the circulatory and hematology systems of the body and their important function in ensuring that the circulatory system plumbing is not leaking (i.e. bleeding) and also not getting plugged up (i.e. thrombosis). A healthy system has adequate numbers of functional platelets, and protein synthesis of the factors needed for a balanced hemostasis system. An adequate amount of Vitamin K is needed for some factors activity. Additionally the absence of any drugs that interfere with platelets or t...
Source: PediatricEducation.org - December 14, 2015 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

FDA Approves Recombinant von Willebrand Factor (FREE)
By the Editors The FDA has approved the first recombinant von Willebrand factor (marketed as Vonvendi) for adults with … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 10, 2015 Category: Primary Care Source Type: news

FDA Approves Baxalta's von Willebrand Disease Drug
Vonvendi is the first FDA-approved recombinant von Willebrand factor for the on-demand treatment and control of bleeding episodes (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - December 9, 2015 Category: Pharmaceuticals Source Type: news

FDA OKs First Recombinant von Willebrand Factor (Vonvendi)FDA OKs First Recombinant von Willebrand Factor (Vonvendi)
The approval of Vonvendi provided an additional therapeutic option for the treatment of bleeding episodes in patients with von Willebrand disease, according to the FDA. FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 8, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA OK's Genetically Engineered Drug for Bleeding Disorder
(MedPage Today) -- Vonvendi is first recombinant von Willebrand factor replacement product (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 8, 2015 Category: American Health Source Type: news

FDA approves first recombinant von Willebrand factor to treat bleeding episodes
The U.S. Food and Drug Administration today approved Vonvendi, von Willebrand factor (Recombinant), for use in adults 18 years of age and older who have von Willebrand disease (VWD). Vonvendi is the first FDA-approved recombinant von Willebrand factor, and is approved for the on-demand (as needed) treatment and control of bleeding episodes in adults diagnosed with VWD. (Source: Food and Drug Administration)
Source: Food and Drug Administration - December 8, 2015 Category: American Health Source Type: news

Vonicog Alfa Safe for Bleeds in Severe von Willebrand Disease (CME/CE)
(MedPage Today) -- Treatment with recombinant von Willebrand factor stabilizes endogenous FVIII:C (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 5, 2015 Category: Hematology Source Type: news

Ablynx reports positive Phase I trial results of caplacizumab to treat TTP
Ablynx has reported positive results from the Phase I trial of its anti-von Willebrand factor Nanobody caplacizumab to treat acquired thrombotic thrombocytopenic purpura (TTP). (Source: Drug Development Technology)
Source: Drug Development Technology - November 28, 2014 Category: Pharmaceuticals Source Type: news

Revised Article-von Willebrand Disease
Von Willebrand disease (VWD) is a bleeding disorder. It affects your blood's ability to clot. If your blood doesn't clot, you can have heavy, hard-to-stop bleeding after an injury. The bleeding can damage your internal organs. Rarely, the bleeding may even cause death. (Source: National Heart, Lung, and Blood Institute Health Topics)
Source: National Heart, Lung, and Blood Institute Health Topics - October 27, 2014 Category: Consumer Health News Source Type: news

What Evaluation Should Be Considered for Heavy Menstrual Bleeding?
Discussion Heavy menstrual bleeding is a common problem. The rates depend on the population and underlying cause, but can occur 30% of adolescent females who go to a gynecologist. Average menstrual blood loss is 30-40 ml. Hypermenorrhea or menorrhagia are regular menstrual cycles that last too long (>7 days) or are too heavy (> 80 ml blood loss). Metrorrhagia is irregular menstrual bleeding. Menometrorrhagia is abnormally heavy bleeding that occurs with an irregular timing. Dysfunctional uterine bleeding is a more generic term describing prolonged, excessive or frequent, unpatterned uterine bleeding that is not relat...
Source: PediatricEducation.org - January 20, 2014 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Featured in NEJM Journal Watch: Von Willebrand Disease — What Women's Health Clinicians Need to Know (FREE)
By the NEJM Journal Watch Editors The American College … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 13, 2013 Category: Primary Care Source Type: news

JCI early table of contents for Nov. 25, 2013
(Journal of Clinical Investigation) This release contains summaries, links to PDFs, and contact information for the following newsworthy papers to be published online, Nov. 25, 2013, in the JCI: Predicting nasopharyngeal carcinoma patient response to radiation therapy; Circadian clock proteins maintain neuronal cell function; Identifying targets of autoantibodies; Balancing T cell populations; Identification of a genetic mutation associated with steroid-resistant nephritic syndrome; Insights into type 2B von Willebrand disease, and more. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 25, 2013 Category: Cancer & Oncology Source Type: news

Researchers link von Willebrand factor to heart-valve calcium deposits
Heart valves calcify over time, and Rice University scientists are beginning to understand why. The Rice lab of bioengineer Jane Grande-Allen found through studies of pigs' heart valves that age plays a critical role in the valves' progressive hardening, and the problem may be due to the infiltration of a protein known as von Willebrand factor (VWF). Tissues from pig valves are commonly used to make human heart-valve replacements... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 11, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Clotting protein hardens aging hearts
(Rice University) The Rice lab of bioengineer Jane Grande-Allen found through studies of pigs' heart valves that age plays a critical role in the valves' progressive hardening, and the problem may be due to the infiltration of a protein known as von Willebrand factor. Tissues from pig valves are commonly used to make human heart-valve replacements. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 7, 2013 Category: Global & Universal Source Type: news

Capsid Modification Strategies for Detargeting Adenoviral Vectors
Adenoviral vectors hold immense potential for a wide variety of gene therapy based applications; however, their efficacy and toxicity is dictated by “off target” interactions that preclude cell specific targeting to sites of disease. A number of “off target” interactions have been described in the literature that occur between the three major capsid proteins (hexon, penton, and fiber) and components of the circulatory system, including cells such as erythrocytes, white blood cells, and platelets, as well as circulatory proteins including complement proteins, coagulation factors, von Willebrand Facto...
Source: Springer protocols feed by Microbiology - October 24, 2013 Category: Microbiology Source Type: news

Heparin, grad students, a clinical revolution and giving credit where it's due
The story of a grad student who overcame remarkable odds only to be denied his moment of glory, or a tale of dark deceit and devilish doings? The story of heparin is as complicated as the chemistry itselfBlood is remarkable.A liquid that carries nutrients, waste products and the ever-vigilant cells of the immune system around the body, blood rapidly turns into a solid when it leaves its veins and arteries and becomes exposed to bodily tissues or the air outside. This process of solidification – clotting, or coagulation – is executed and controlled by a complex set of reactions and interactions primarily involvi...
Source: Guardian Unlimited Science - September 4, 2013 Category: Science Authors: Richard P Grant Tags: theguardian.com Blogposts Science Source Type: news

Physicists Probe Stress-Induced Changes In Clot-Forming Protein
New research from Rice University, Baylor College of Medicine (BCM) and the Puget Sound Blood Center (PSBC) has revealed how stresses of flow in the small blood vessels of the heart and brain could cause a common protein to change shape and form dangerous blood clots. The scientists were surprised to find that the proteins could remain in the dangerous, clot-initiating shape for up to five hours before returning to their normal, healthy shape. The study -- the first of its kind -- focused on a protein called von Willebrand factor, or VWF, a key player in clot formation... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 8, 2013 Category: Consumer Health News Tags: Blood / Hematology Source Type: news